212. Sex Med and Urology - Top Takeaways at the 2023 AUA conference

You Are Not Broken

Kelly Casperson, MD

Medicine, Health & Fitness

5 • 743 Ratings

🗓️ 21 May 2023

⏱️ 40 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

I went to the 2023 American Urologic Association's National Conference. Here are some top takeaways and thoughts. So much on this week’s podcast! Low hormones in men and women — can increase risk for cardiovascular disease Women have a decreased risk of heart attack and stroke when started on hormones in the safety window of menopause (first 10 years) The Traverse study paper coming out in two months - can’t wait! Testosterone is not a gendered hormone All bones need testosterone Women in early menopause should be on hormones at least until natural age of menopause to decrease risk of cardiovascular disease, osteoporosis (NAMS guidelines and this indication has FDA approval). Equality in healthcare Three new oral testosterone pills on the market for men, not for women We need to focus on brains and bones health in women just as much as we do for men Treat women the same in healthcare Did you know the UK is requiring doctors to talk to their patients at age 50 about menopause? Amazing! If hormones are so dangerous, why don’t we stop estrogen in trans women after the age of 50 - a thought exercise on how we think about giving hormones to all bodies - Is staying on hormones during menopause gender affirming care? Oral DHEA supplements — what’s the deal? Bulkamid — urethral filler for stress incontinence ECoin training Prolapse repair in premenopausal women Should we offer it or no? Male infertility is associated with shorter life expectancy Marijuana affect sperm Using testosterone for maintenance of vaginal health Michael Pearlman balance scale of desire More about Addyi (filbanserin) Importance of elastin and collagen Very small percentage of women have cervical orgasms - but it matters. New technology that @mysteryvibe is releasing to help with period cramps --- Send in a voice message: https://podcasters.spotify.com/pod/show/kj-casperson/message Learn more about your ad choices. Visit megaphone.fm/adchoices

Transcript

Click on a timestamp to play from that location

0:00.0	You are listening to You Are Not Broken, the only podcast that combines science, medicine, and psychology to re-educate your brain and help you live your best love life.
0:11.4	And I'm your host, board certified female urologist, Dr. Kelly Casperson.
0:16.4	So recording here, if you just joined me, recording here live from Chicago and the American
0:22.1	Neurologic Association, day one, I've spent the morning at the sexual, North American
0:27.8	sexual medicine, I don't know, like Ishwish took me a long time to pronounce, and now I have
0:32.3	to pronounce the sexual, North American sexual medicine, SM menif, say, I don't know, they did
0:37.3	great. But this morning session was all
0:39.6	about hormones. First, the hormones was in men, then it was transgender, then it was women of note.
0:44.8	The people who are 51% of the population, the women had the least amount of lectures on hormones.
0:49.6	Women had one lecture. Transcare had two, and male hormones had more than two.
0:57.2	All right.
0:57.9	So in men, we know that low hormones, aka testosterone, increases a risk for cardiovascular disease.
1:04.4	News alert, we know this in women too.
1:06.8	Women after menopause who take exogenous estrogen have a significantly decreased cardiovascular risk.
1:14.6	It's not used as primary prevention, but we do know they have a decreased risk of heart attack and stroke when started in the safety window of menopause, which is in the first 10 years.
1:24.9	So we know this in men, we know this in women. So the FDA
1:29.7	has a black box warning on testosterone, which is only an FDA approved product for men,
1:34.4	showing that testosterone might cause increased cardiovascular risk, but we don't have any good
1:39.0	data to show that. And we do know that men with low testosterone have an increased cardiovascular risk.
1:45.5	And the European equivalent of the FDA does not have a black box warning on testosterone being a
1:51.1	risk factor for cardiovascular risk because we don't have any great data.
1:54.9	But the Travers trial, which is a double-blind placebo-controlled trials coming out in two months,
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Kelly Casperson, MD, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Kelly Casperson, MD and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.